AIM Vaccine Co., Ltd. (HKG:6660)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.380
-0.120 (-4.80%)
Apr 29, 2026, 4:08 PM HKT
-26.09%
Market Cap 3.07B
Revenue (ttm) 1.30B
Net Income (ttm) -751.66M
Shares Out 1.23B
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 465,000
Average Volume 1,404,080
Open 2.500
Previous Close 2.500
Day's Range 2.350 - 2.500
52-Week Range 2.130 - 6.010
Beta 0.20
RSI 38.64
Earnings Date Mar 30, 2026

About AIM Vaccine

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infecti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 1,466
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6660
Full Company Profile

Financial Performance

In 2025, AIM Vaccine's revenue was 1.17 billion, a decrease of -9.29% compared to the previous year's 1.29 billion. Losses were -675.46 million, 143.6% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.